Product Certification
In 2023, The Board of Medicine team published some of the world’s first comprehensive clinical guidelines recommending evidence-based treatment programs for improving harm-reduction when managing opioid dependence and chronic pain using cannabinoids entitled: An answered call for aid? Cannabinoid clinical framework for the opioid epidemic
For cannabinoid products to be successfully integrated into the clinical practice of medicine to avoid unnecessary harm from over-prescribed medications such as opioids, these products must be independently vetted and certified by a governing body to ensure product safety.
In collaboration with best-in-class product manufacturers and world-renowned medical experts, The Board has independently verified and certified some of the first physician-approved cannabinoid products to guide clinicians and patients toward the safest alternatives for risk-reduction. The Board of Medicine seal present on cannabinoid products serves as confirmation that the product has been tested and verified by The Board to be what it says it is on the label, without any harmful levels of contaminants.
Blue Certification (Tier 3)
Third party validation stating:
No medicine should contain contaminants to include (at acceptable levels):
- Pesticides
- Herbicides
- Fungicides
- Heavy Metals
- Solvents - harmful solvents
- Fillers known to be toxic
All medicine should be what it says it is (ie. on the label) - within 10% variance
Cultivation is in compliance with state
Organic farming practices
Full panel testing
Silver Certification (Tier 2)
Blue criteria plus:
Broad Spectrum or Full Spectrum (No isolate)
Products sourced from USA
Full panel testing - including terpene profile
SOPs for farming and production for reproducible processes
Gold Certification (Tier 1)
Silver criteria plus:
Known source of seed & stable genetics
Organic, Regenerative farming practices
Flower used in extraction
Full spectrum
Subcannabinoids and wide spectrum of terpenes and flavonoids present
Subcritical CO2 or ethanol extraction
Verified educational content
Independent
In 2023, The Board of Medicine team published some of the world’s first comprehensive clinical guidelines recommending evidence-based treatment programs for improving harm-reduction when managing opioid dependence and chronic pain using cannabinoids entitled: An answered call for aid? Cannabinoid clinical framework for the opioid epidemic
For cannabinoid products to be successfully integrated into the clinical practice of medicine to avoid unnecessary harm from over-prescribed medications such as opioids, these products must be independently vetted and certified by a governing body to ensure product safety.
In collaboration with best-in-class product manufacturers and world-renowned medical experts, The Board has independently verified and certified some of the first physician-approved cannabinoid products to guide clinicians and patients toward the safest alternatives for risk-reduction. The Board of Medicine seal present on cannabinoid products serves as confirmation that the product has been tested and verified by The Board to be what it says it is on the label, without any harmful levels of contaminants.
Blue Certification (Tier 3)
Third party validation stating:
No medicine should contain contaminants to include (at acceptable levels):
- Pesticides
- Herbicides
- Fungicides
- Heavy Metals
- Solvents - harmful solvents
- Fillers known to be toxic
All medicine should be what it says it is (ie. on the label) - within 10% variance
Cultivation is in compliance with state
Organic farming practices
Full panel testing
Silver Certification (Tier 2)
Blue criteria plus:
Broad Spectrum or Full Spectrum (No isolate)
Products sourced from USA
Full panel testing - including terpene profile
SOPs for farming and production for reproducible processes
Gold Certification (Tier 1)
Silver criteria plus:
Known source of seed & stable genetics
Organic, Regenerative farming practices
Flower used in extraction
Full spectrum
Subcannabinoids and wide spectrum of terpenes and flavonoids present
Subcritical CO2 or ethanol extraction
Verified educational content
Independent
In 2023, The Board of Medicine team published some of the world’s first comprehensive clinical guidelines recommending evidence-based treatment programs for improving harm-reduction when managing opioid dependence and chronic pain using cannabinoids entitled: An answered call for aid? Cannabinoid clinical framework for the opioid epidemic
For cannabinoid products to be successfully integrated into the clinical practice of medicine to avoid unnecessary harm from over-prescribed medications such as opioids, these products must be independently vetted and certified by a governing body to ensure product safety.
In collaboration with best-in-class product manufacturers and world-renowned medical experts, The Board has independently verified and certified some of the first physician-approved cannabinoid products to guide clinicians and patients toward the safest alternatives for risk-reduction. The Board of Medicine seal present on cannabinoid products serves as confirmation that the product has been tested and verified by The Board to be what it says it is on the label, without any harmful levels of contaminants.
Blue Certification (Tier 3)
Third party validation stating:
No medicine should contain contaminants to include (at acceptable levels):
- Pesticides
- Herbicides
- Fungicides
- Heavy Metals
- Solvents - harmful solvents
- Fillers known to be toxic
All medicine should be what it says it is (ie. on the label) - within 10% variance
Cultivation is in compliance with state
Organic farming practices
Full panel testing
Silver Certification (Tier 2)
Blue criteria plus:
Broad Spectrum or Full Spectrum (No isolate)
Products sourced from USA
Full panel testing - including terpene profile
SOPs for farming and production for reproducible processes
Gold Certification (Tier 1)
Silver criteria plus:
Known source of seed & stable genetics
Organic, Regenerative farming practices
Flower used in extraction
Full spectrum
Subcannabinoids and wide spectrum of terpenes and flavonoids present
Subcritical CO2 or ethanol extraction
Verified educational content
Independent
Samples of all products, current COA’s and seed-to-sale information (as much as is available) must be mailed to The Board of Medicine product evaluation team. The mailing address will be provided upon receipt of payment. The $1500.00 fee covers the time required for product evaluation team to review the product and provide feedback. While submission does not guarantee certification, The Board’s goal is to grant a certification seal to all products that meet minimum criteria for certification (blue - tier 3). Please be sure to review the minimum certification criteria prior to submitting your product. The Board’s fees of $1500.00 do not cover the additional cost of Gold certification (Tier 1) testing by the Banned Substances Control Group (BSCG). Passing BSCG testing is required for products to obtain Gold certification status, which makes them eligible for recommendation to elite athletics organizations and individual elite athletes and athletics groups worldwide.